Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04656561 · ClinicalTrials.gov registry record · Phase 2
A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy
A Phase 2 study of Geographic Atrophy, sponsored by Annexon.
- Completed
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT04656561 is a Phase 2 study of Geographic Atrophy that has completed, run by Annexon. The registered enrollment target is 270 participants, above the 212-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (27% higher). The trial reports 20 study locations across 7 states.
The verdict
NCT04656561, a Phase 2 study of Geographic Atrophy, has completed, sponsored by Annexon.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with geographic atrophy. The total duration of participation is expected to be approximately 19 months.
Conditions Studied
Interventions
- OTHER Sham comparator
- DRUG ANX007
Study Locations (20)
California
- Site 31 - Bakersfield
- Site 2 - Beverly Hills
- Site 19 - Mountain View
- Site 23 - Pasadena
- Site 37 - Poway
- Site 17 - Sacramento
- Site 18 - Santa Ana
- Site 33 - Walnut Creek
Florida
- Site 12 - Fort Myers
- Site 53 - Jacksonville
- Site 26 - Pensacola
- Site 16 - Pinellas Park
- Site 43 - Sarasota
- Site 28 - St. Petersburg
- Site 6 - Winter Haven
Arizona
- Site 5 - Phoenix
Connecticut
- Site 39 - Waterford
Georgia
- Site 42 - Augusta
Kentucky
- Site 11 - Lexington
Maryland
- Site 1 - Hagerstown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2021-02-26 |
| Est. Completion | 2023-09-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04656561
The ClinicalTrials.gov registry entry for NCT04656561 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 270 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 212-participant average among 27 other Geographic Atrophy trials with a reported enrollment target (27% higher). The listed sponsor is Annexon, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Geographic Atrophy appearing as the primary indexed condition, and to 2 interventions - of which Sham comparator is the first listed.
NCT04656561 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Florida, Arizona.
Frequently Asked Questions
What is clinical trial NCT04656561 about?
NCT04656561 is a clinical study titled "A Study Investigating the Efficacy and Safety of Intravitreal Injections of ANX007 in Patients With Geographic Atrophy". This study is being conducted in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) to determine if intravitreal (IVT) injections of ANX007 reduce GA lesion growth rate. The results will be used to guide further development of ANX007 in participants with ge...
What is the current status of trial NCT04656561?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2021-02-26. Estimated completion is 2023-09-13.
What conditions does trial NCT04656561 study?
This clinical trial studies the following conditions: Geographic Atrophy.
What interventions are being tested in trial NCT04656561?
The interventions under investigation include: Sham comparator (OTHER), ANX007 (DRUG).
Who is sponsoring clinical trial NCT04656561?
This trial is sponsored by Annexon, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04656561 being conducted?
This trial has 20 study locations across Arizona, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Geographic Atrophy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
SGLT2 Inhibitors in Geographic Atrophy
RECRUITING · Phase 2
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)
RECRUITING · Phase 2
-
A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251
RECRUITING · Phase 2
-
A Study to Test Whether BI 771716 Helps People With an Advanced Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Test Different Doses of BI 1584862 in People With a Distinct Form of Age-related Macular Degeneration (AMD) Called Geographic Atrophy
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.